|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Acetylon Pharmaceuticals Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for ACY-1215 in Multiple Myeloma
12/12/2011 7:29:51 AM
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced the publication of preclinical safety and effectiveness results for its oral selective HDAC6 inhibitor drug candidate, ACY-1215, which has recently entered Phase 1-2a clinical trials in North America. The results include favorable pharmacokinetic and pharmacodynamic properties that confirm HDAC6 selectivity and potent anti-cancer activity for the small molecule drug candidate as well as cellular evidence for the potential to limit painful and disabling bone disease in multiple myeloma. The results have been published in a special on-line edition of the scientific journal of the American Society of Hematology (ASH), Blood, 118(21), Abstracts 2908 and 2912, Nov. 17, 2011) and were be presented on Sunday, December 11th, at the 53rd ASH Annual Meeting and Exposition in San Diego, California.
|
|
|
|
|
|
|
|
|
|
|